MultiCell Technologies Inc. subsidiary inks worldwide licensing
for medical devices IP
from International Business Times
MultiCell Technologies Inc. and its majority owned subsidiary Xenogenics Corp. jointly announced Xenogenics' acquisition of Ideal™ BioStent, as well as Xenogenics' worldwide exclusive license deal with Rutgers University for rights to certain intellectual property related to the Ideal BioStent. Analysts forecast the multi-billion dollar interventional cardiology and intravascular stent market to reach $4.6 billion at a growth rate of 3 percent to 4 percent annually. Advances in the market center on medical devices innovation that address long-term safety concerns, including the improvement of blood vessel health. The Ideal BioStent's is a layered technology that integrates different combinations of polymers and drugs to enable the optimization of the delivery of combination drug therapies to provide superior clinical results.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063